Akari Therapeutics H1 2023 Net Loss Of $2.99M Versus $10.8M A Year Ago, Cash Balance Of Approximately $7.2M Sufficient To Fund Operations Into Q1 Of 2024
Author: Benzinga Newsdesk | September 29, 2023 08:04am
Akari Therapeutics (NASDAQ:AKTX) will report on H1 2023.